Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
This position is supported by the results of a recent study that suggest that achieving a HbA1c target of 300 mg/g), lixisenatide reduced the placebo-adjusted mean percentage change in UACR by 39.2% (95% confidence interval 9.8 to 68.5%
It was so embarrassing
USA 110 , 1204812053 (2013)
10.1161/CIRCRESAHA.116.309326 Circ Res
Shen Z, Liang X, Rogers CQ, Rideout D, You M
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
